本文已被：浏览 216次 下载 147次
投稿时间：2025-06-19 网络发布日期：2026-01-27
投稿时间：2025-06-19 网络发布日期：2026-01-27
中文摘要: 目的 分析黄芪四君子汤联合罗格列酮对2型糖尿病（T2DM）患者疗效、中医证候积分、糖脂代谢、胰岛功能的影响。方法 前瞻性选取在 2022 年 1 月 1 日至 2023 年 3 月 31 日于石家庄市第二医院就诊的 120 例T2DM患者，采用随机数字表法分为研究组与对照组，各60例。对照组口服罗格列酮片，研究组在此基础上加服黄芪四君子汤。比较两组各项指标变化。结果 治疗 3 个月后，研究组的总有效率高于对照组（96.67% vs86.67%，χ2=7.737，P=0.021）。治疗后两组中医证候积分均降低，研究组更低（P<0.05）。治疗后，两组空腹血糖（FBG）及餐后 2 h 血糖（2hPG）、糖化血红蛋白（HbA1c）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL-C）、总胆固醇（TC）、空腹胰岛素（FINS）、胰岛素抵抗指数（HOMA-IR）水平低于治疗前，β细胞功能指数（HOMA-β）、高密度脂蛋白胆固醇（HDL-C）、餐后2 h C肽（2hC-P）水平高于治疗前（P<0.05）。治疗后，研究组糖脂代谢指标、FINS和HOMA-IR的降幅更大，而HOMA-β、HDL-C和2hC-P的升高更明显（P<0.05）。研究组和对照组总不良反应发生率差异无统计学意义（13.33% vs 10.00%，χ2=0.323，P=0.570）。结论 黄芪四君子汤联合罗格列酮能显著改善T2DM患者的临床症状及糖脂代谢指标，且安全性良好。
Abstract:Objective To investigate the therapeutic effects，Chinese medicine syndrome score，glycolipid metabolism and islet function of Huangqi Sijunzi Decoction combined with rosiglitazone on type 2 diabetes mellitus（T2DM）patients. Methods A prospective study was conducted on 120 T2DM patients who visited the Second Hospital of Shijiazhuang from 1 January 2022 to 31 March 2023. The patients were randomly divided into a research group and a control group using a random number table method，with 60 patients in each group. The control group received oral administration of rosiglitazone tablets，while the research group received additional administration of Huangqi Sijunzi Decoction. The changes of various indicators between the two groups were compared. Results The research group demonstrated a clinically superior total effective rate compared to the control group after 3 months of treatment（96.67%vs 86.67%，χ2=7.737，P=0.021）. After treatment，the Chinese medicine syndrome scores of both groups decreased，and those of the research group were even lower（P<0.05）. After treatment，the levels of fasting blood glucose（FBG），2-hour postprandial blood glucose（2hPG），glycated hemoglobin（HbA1c），triglyceride（TG），low -density lipoprotein cholesterol（LDL-C），and total cholesterol（TC），fasting insulin（FINS），and homeostatic model assessment of insulin resistance（HOMA-IR）in both groups were lower than before treatment，while the levels of high-density lipoproteincholesterol（HDL-C），2-hour postprandial C-peptide（2hC-P），and HOMA-β were higher than before treatment（P<0.05）. After treatment，the levels of all indicators of glucose metabolism and all indicators of lipid metabolism，FINS，HOMA-IR in the research group were lower than those in the control group，while HDL -C，2hC -P，and homeostasis model assessment-β（HOMA-β）were higher than those in the control group（P<0.05）. There was no statistically significant difference in the total incidence of adverse reactions between the research group and control group（13.33%vs 10.00%，χ2=0.323，P=0.570）. Conclusion The combination of Huangqi Sijunzi Decoction and rosiglitazone can significantly improve clinical symptoms and glycolipid metabolism indicators in T2DM patients，and the safety is high.
keywords: Type 2 diabetes Huangqi Sijunzi Decoction Rosiglitazone Chinese medicine symptoms Blood lipid
文章编号： 中图分类号：R587.1 R255.4 文献标志码：A
基金项目:河北省中医药管理局科研计划项目（2024138）
附件
| Author Name | Affiliation |
| PEI Hua*，HU Wenjing，LI Zhenzhen，SUN Ran，ZHAO Nawei，WANG Chen | *Department of Endocrinology,The Second Hospital of Shijiazhuang,Shijiazhuang,Hebei 050051,China |
引用文本：
裴华,胡文净,李贞贞,等.黄芪四君子汤联合罗格列酮治疗2型糖尿病的疗效[J].中国临床研究,2026,39(1):47-51.
裴华,胡文净,李贞贞,等.黄芪四君子汤联合罗格列酮治疗2型糖尿病的疗效[J].中国临床研究,2026,39(1):47-51.